Aptiv assumed with Top Pick, Outperform rating at Wolfe Research

Wolfe Research assumed coverage of Aptiv with an Outperform rating, Top Pick designation, and $89 price target. The firm sees the near-term narrative around Aptiv shifting from one focused on the top-line to one focused on earnings, though its organic revenue growth is also expected to be four percantage points above industry production in 2024, the analyst tells investors in a research note. Wolfe sees that remaining in the 4-5 point range through 2026.